SeaStar Medical Holding Corporation (ICU)
ICUNASDAQ-CMMedical/Dental Instruments
$1.90
-0.0590 (-3.01%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.90 +0.05%
- Market cap
- $10.10m
- P/E
- –
- EPS, last 4 quarters
- $-3.91
- Dividend yield
- –
- Day range
- $1.90 to $1.96
- 52-week range
- $1.84 to $5.38
- Average volume
- 180.5k
- Previous close
- $1.96
Earnings
next estimate $-0.9500Next report Nov 11, 2026
Sep 2025
–
Dec 2025
+17.5%
Mar 2026
-23.3%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $183.0k | $420.0k | $495.0k | $615.0k |
| Gross profit | $169.0k | $408.0k | $449.0k | $561.0k |
| Operating income | -$3.58m | -$3.02m | -$3.60m | -$3.79m |
| Net income | -$3.47m | -$2.90m | -$3.52m | -$3.73m |
Last four quarters: revenue $1.71m, margin -795.5%, free cash flow –
News
8 latest- SeaStar Medical Holding Corporation Announces FDA Determination on QUELIMMUNE Post-Approval Study Requirements on November 3, 2026Fintel · Nov 3, 2026
- FDA Confirms SeaStar Medical Meets QUELIMMUNE Post-Approval Study Requirements RTTNews · Nov 3, 2026
- SeaStar Reports Higher Survival With QUELIMMUNE In Pediatric Kidney Injury Analysis RTTNews · Oct 23, 2026
- SeaStar Gets FDA Breakthrough Device Designation For SCD In Adult Sepsis; Stock Up RTTNews · Oct 7, 2026
- SeaStart Medical Raises $3.3 Million Through Warrant Exercises; Stock Down RTTNews · Oct 5, 2026
- Biotech Stocks Move Higher - NIVF +25%, ICU +23%, ATRA +11%, INDP +9% RTTNews · Oct 2, 2026
- SeaStar Medical (ICU) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 12, 2026
- SeaStar Medical Gains 13% Ahead Of Q2 Results As Critical Care Pipeline Advances RTTNews · Aug 10, 2026
The company
SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical's first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- seastarmedical.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.